WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright
23
rd
Annual Global Investment Conference
. Details of the Company’s participation are as follows:
|
Conference: H.C. Wainwright 23 rd Annual Global Investment Conference |
|
|
Dates: September 13-15, 2021 |
|
| Format: |
Fireside chat available on-demand beginning September 13 th at 7:00am ET |
| One-on-one investor meetings | |
About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting
Acinetobacter baumannii
infections), zoliflodacin (targeting
Neisseria gonorrhoeae
infections), ETX0462 (targeting multiple Gram-negative pathogens including
Pseudomonas aeruginosa
) and ETX0282CPDP (targeting
Enterobacteriaceae
infections). For more information, visit
www.entasistx.com
.
Entasis Contacts
Company:
Kyle Dow
Entasis Therapeutics
(781) 810-0114
[email protected]
Investor Relations:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
[email protected]
